CollPlant Biotechnologies (CLGN) Cash & Equivalents (2017 - 2026)

CollPlant Biotechnologies has reported Cash & Equivalents for 10 years, with the latest figure at $5.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 53.05% year-over-year to $5.6 million; the trailing twelve-month figure through Mar 2026 stood at $5.6 million (down 53.05% YoY), and the FY2025 full-year result was $5.6 million, down 79.04% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $5.6 million, roughly flat from $5.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $41.1 million in Q1 2022, with the low at $5.6 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $21.3 million across 5 years, with a median of $22.3 million in 2023.
• Annual changes were most pronounced in 2023 — Cash & Equivalents surged 123.3% — and 2024, when it tumbled 60.12%.
• CollPlant Biotechnologies' Cash & Equivalents stood at $13.4 million in 2022, then jumped by 123.3% to $29.9 million in 2023, then plunged by 60.12% to $11.9 million in 2024, then slumped by 53.05% to $5.6 million in 2025, then changed by 0.0% to $5.6 million in 2026.
• The last three Cash & Equivalents figures came in at $5.6 million (Q1 2026), $5.6 million (Q4 2025), and $11.9 million (Q3 2025), per Business Quant data.